C-Met receptor regulation by angiotensin IV (AT4) receptor ligands
US9066901B2 · kind B2 · utility
2Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 12, 2012 |
| Grant date | Jun 30, 2015 |
| Priority date | — |
| Expiry date | Jul 12, 2032 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/044
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Angiotensin-like factor compositions and methods for using them to diagnose, prevent and/or treat conditions associated with c-Met dysregulation, are provided. The conditions include cancer, obesity, conditions associated with obesity, and neurodegenerative diseases such as general dementia, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, traumatic brain injury and spinal cord trauma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.